​

Tvardi Therapeutics (TVRD) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

TVRD Stock Forecast

Tvardi Therapeutics (TVRD) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $8.75, with a high of $13.00 and a low of $3.00. This represents a 605.65% increase from the last price of $1.24.

TVRD Stock Rating

Tvardi Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (50.00%), 1 Hold (25.00%), 1 Sell (25.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 1 2 Strong Sell Sell Hold Buy Strong Buy

TVRD Price Target Upside V Benchmarks

TypeNameUpside
StockTvardi Therapeutics605.65%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-27
Avg Price Target-$11.50$15.00
Last Closing Price$1.24$1.24$1.24
Upside/Downside-827.42%1109.68%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26251-19
Sep, 26251-19
Aug, 26251-19
Jul, 26-53-19
Jun, 26-43-18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 08, 2026Piper Sandler$13.00$5.00160.00%948.39%
Jul 08, 2026Ryan DeschnerUBS$10.00$3.10222.58%706.45%
Jun 08, 2026H.C. Wainwright$9.00$2.89211.42%625.81%
Apr 20, 2026Barclays$3.00$3.39-11.50%141.94%
Oct 13, 2025Barclays$5.00$6.69-25.26%303.23%
Oct 13, 2025Yasmeen RahimiPiper Sandler$4.00$6.54-38.84%222.58%
Oct 13, 2025Etzer DaroutBarclays$61.00$41.6046.63%4819.35%
Jun 12, 2025Yasmeen RahimiPiper Sandler$78.00$26.11198.74%6190.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 08, 2026Piper SandlerNeutralOverweightupgrade
Jul 08, 2026UBSOutperformupgrade
Jun 08, 2026H.C. WainwrightBuyinitialise
Apr 20, 2026BarclaysNegativeUnderweightdowngrade
Oct 14, 2025Raymond JamesOutperformMarket Performdowngrade
Oct 13, 2025BarclaysOverweightNegativedowngrade
Oct 13, 2025Cantor FitzgeraldOverweightNeutraldowngrade
Oct 13, 2025Piper SandlerOverweightNeutraldowngrade
Oct 13, 2025BarclaysOverweightinitialise
Jul 14, 2025Raymond JamesOutperforminitialise

Financial Forecast

EPS Forecast

Dec 25 Dec 26 Dec 27
Dec 25Dec 26Dec 27
Reported---
Avg Forecast$-3.16$-4.60-
High Forecast$-3.16$-4.60-
Low Forecast$-3.16$-4.60-
Surprise %---

Revenue Forecast

Dec 25 Dec 26 Dec 27
Dec 25Dec 26Dec 27
Reported---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

Net Income Forecast

Dec 25 Dec 26 Dec 27
Dec 25Dec 26Dec 27
Reported---
Avg Forecast$-29.56M$-43.04M-
High Forecast$-29.56M$-43.04M-
Low Forecast$-29.56M$-43.04M-
Surprise %---

TVRD Forecast FAQ

Is Tvardi Therapeutics stock a buy?

Tvardi Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Tvardi Therapeutics is a favorable investment for most analysts.

What is Tvardi Therapeutics's price target?

Tvardi Therapeutics's price target, set by 4 Wall Street analysts, averages $8.75 over the next 12 months. The price target range spans from $3 at the low end to $13 at the high end, suggesting a potential 605.65% change from the previous closing price of $1.24.

How does Tvardi Therapeutics stock forecast compare to its benchmarks?

Tvardi Therapeutics's stock forecast shows a 605.65% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Tvardi Therapeutics over the past three months?

  • October 2026: 22.22% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 11.11% Strong Sell.
  • September 2026: 22.22% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 11.11% Strong Sell.
  • August 2026: 22.22% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 11.11% Strong Sell.

What is Tvardi Therapeutics’s EPS forecast?

Tvardi Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.16, marking a 0% decrease from the reported - in 2024. Estimates for the following years are $-4.6 in 2026, and $0 in 2027.

What is Tvardi Therapeutics’s revenue forecast?

Tvardi Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported - in 2024. The forecast for 2026 is $0, and $0 for 2027.

What is Tvardi Therapeutics’s net income forecast?

Tvardi Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-29.564M, representing a 0% decrease from the reported - in 2024. Projections indicate $-43.035M in 2026, and $0 in 2027.